PTCT: Broad PKU launch, strong pipeline, and global expansion drive growth and profitability
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway. Recent acquisitions and disciplined OpEx support sustainable profitability.Bas…